Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
22 hedge funds and large institutions have $507K invested in Bellerophon Therapeutics, Inc. in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 22 → 22 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
1.05% less ownership
Funds ownership: 11.46% → 10.41% (-1.1%)
39% less capital invested
Capital invested by funds: $825K → $507K (-$318K)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$58.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$21K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$7.54K |
| 4 |
Two Sigma Investments
New York
|
+$4.99K |
| 5 |
Two Sigma Advisers
New York
|
+$3.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$18K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$14.8K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$9.86K |
| 4 |
Renaissance Technologies
New York
|
-$8.77K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$7.14K |
BLPH Hedge Fund Activity: Q3 2023 in Review
22 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q3 2023, worth a combined $507K — down 39% from $825K a quarter earlier.
Fund positioning in BLPH was balanced in Q3 2023: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 8 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $58.1K. The largest seller was Virtu Financial, exiting entirely with an estimated $18K sold.
- 22 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $507K of Bellerophon Therapeutics, Inc. stock for Q3 2023, down 39% quarter-over-quarter.
- 4 funds opened new Bellerophon Therapeutics, Inc. positions in Q3 2023 and 4 closed out, a net change of 0 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q3 2023 was Acadian Asset Management, an estimated $58.1K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q3 2023 was Virtu Financial, an estimated $18K sold.
Based on aggregated 13F filings for Q3 2023.